These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34676158)
1. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data. Ye P; Yang Y; Zhang L; Zheng G Front Oncol; 2021; 11():658262. PubMed ID: 34676158 [TBL] [Abstract][Full Text] [Related]
2. Characterization of alternative splicing events and prognostic signatures in breast cancer. Han P; Zhu J; Feng G; Wang Z; Ding Y BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836 [TBL] [Abstract][Full Text] [Related]
3. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma. Liu Y; Jia W; Li J; Zhu H; Yu J Front Oncol; 2020; 10():587343. PubMed ID: 33117720 [No Abstract] [Full Text] [Related]
4. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing. Zhang D; Zou D; Deng Y; Yang L J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089 [TBL] [Abstract][Full Text] [Related]
5. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data. Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B Front Oncol; 2020; 10():1257. PubMed ID: 32793502 [No Abstract] [Full Text] [Related]
6. Role of alternative splicing events in endometrial cancer prognosis. Liu J; Mi C; Long W; Sun T Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583 [TBL] [Abstract][Full Text] [Related]
7. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas. Yang L; He Y; Zhang Z; Wang W PeerJ; 2019; 7():e8245. PubMed ID: 31844595 [TBL] [Abstract][Full Text] [Related]
8. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data. Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810 [TBL] [Abstract][Full Text] [Related]
9. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma. Lai J; Yang H; Xu T BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080 [TBL] [Abstract][Full Text] [Related]
10. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas. Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970 [TBL] [Abstract][Full Text] [Related]
12. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial Cancer. Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251 [TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333 [TBL] [Abstract][Full Text] [Related]
15. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing. Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y Front Genet; 2020; 11():534. PubMed ID: 32595697 [TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma. Sun JR; Kong CF; Lou YN; Yu R; Qu XK; Jia LQ Front Genet; 2020; 11():796. PubMed ID: 32793288 [TBL] [Abstract][Full Text] [Related]
17. Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma. Meng T; Huang R; Zeng Z; Huang Z; Yin H; Jiao C; Yan P; Hu P; Zhu X; Li Z; Song D; Zhang J; Cheng L Front Bioeng Biotechnol; 2019; 7():270. PubMed ID: 31681747 [No Abstract] [Full Text] [Related]
18. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer. Shao XY; Dong J; Zhang H; Wu YS; Zheng L Front Genet; 2020; 11():726. PubMed ID: 32793282 [TBL] [Abstract][Full Text] [Related]
19. Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma. Lin G; Wang H; Wu Y; Wang K; Li G Front Mol Biosci; 2021; 8():682471. PubMed ID: 34295922 [No Abstract] [Full Text] [Related]
20. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma. Xing L; Zhang X; Tong D DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]